Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)

Akira Shimada; Eiji Kawasaki; Norio Abiru; Takuya Awata; Yoichi Oikawa; Haruhiko Osawa; Hiroshi Kajio; Junji Kozawa; Kazuma Takahashi; Daisuke Chujo; Shinsuke Noso; Tomoyasu Fukui; Junnosuke Miura; Kazuki Yasuda; Hisafumi Yasuda; Akihisa Imagawa; Hiroshi Ikegami

doi:10.1111/jdi.14267

Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)

Akira Shimada^*, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo, Shinsuke Noso, Tomoyasu Fukui, Junnosuke Miura, Kazuki Yasuda, Hisafumi Yasuda, Akihisa Imagawa, Hiroshi Ikegami

^*Corresponding author for this work

Center for Clinical and Translational Research

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

Original language	English
Pages (from-to)	163-168
Number of pages	6
Journal	Journal of Diabetes Investigation
Volume	16
Issue number	1
DOIs	https://doi.org/10.1111/jdi.14267
State	Published - 2025/01

Keywords

Hypoglycemic drugs
Insulin-independent state
Slowly progressive insulin-dependent diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdi.14267

Cite this

Shimada, A., Kawasaki, E., Abiru, N., Awata, T., Oikawa, Y., Osawa, H., Kajio, H., Kozawa, J., Takahashi, K., Chujo, D., Noso, S., Fukui, T., Miura, J., Yasuda, K., Yasuda, H., Imagawa, A., & Ikegami, H. (2025). Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version). Journal of Diabetes Investigation, 16(1), 163-168. https://doi.org/10.1111/jdi.14267

@article{511849b07bc34e029e97c484c3b09459,

title = "Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)",

abstract = "Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.",

keywords = "Hypoglycemic drugs, Insulin-independent state, Slowly progressive insulin-dependent diabetes",

author = "Akira Shimada and Eiji Kawasaki and Norio Abiru and Takuya Awata and Yoichi Oikawa and Haruhiko Osawa and Hiroshi Kajio and Junji Kozawa and Kazuma Takahashi and Daisuke Chujo and Shinsuke Noso and Tomoyasu Fukui and Junnosuke Miura and Kazuki Yasuda and Hisafumi Yasuda and Akihisa Imagawa and Hiroshi Ikegami",

note = "Publisher Copyright: {\textcopyright} 2024 The Japan Diabetes Society. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.",

year = "2025",

month = jan,

doi = "10.1111/jdi.14267",

language = "英語",

volume = "16",

pages = "163--168",

journal = "Journal of Diabetes Investigation",

issn = "2040-1116",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

Shimada, A, Kawasaki, E, Abiru, N, Awata, T, Oikawa, Y, Osawa, H, Kajio, H, Kozawa, J, Takahashi, K, Chujo, D, Noso, S, Fukui, T, Miura, J, Yasuda, K, Yasuda, H, Imagawa, A & Ikegami, H 2025, 'Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)', Journal of Diabetes Investigation, vol. 16, no. 1, pp. 163-168. https://doi.org/10.1111/jdi.14267

TY - JOUR

T1 - Practice guideline

T2 - Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)

AU - Shimada, Akira

AU - Kawasaki, Eiji

AU - Abiru, Norio

AU - Awata, Takuya

AU - Oikawa, Yoichi

AU - Osawa, Haruhiko

AU - Kajio, Hiroshi

AU - Kozawa, Junji

AU - Takahashi, Kazuma

AU - Chujo, Daisuke

AU - Noso, Shinsuke

AU - Fukui, Tomoyasu

AU - Miura, Junnosuke

AU - Yasuda, Kazuki

AU - Yasuda, Hisafumi

AU - Imagawa, Akihisa

AU - Ikegami, Hiroshi

PY - 2025/1

Y1 - 2025/1

N2 - Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

AB - Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

KW - Hypoglycemic drugs

KW - Insulin-independent state

KW - Slowly progressive insulin-dependent diabetes

UR - http://www.scopus.com/inward/record.url?scp=85208798750&partnerID=8YFLogxK

U2 - 10.1111/jdi.14267

DO - 10.1111/jdi.14267

M3 - 学術論文

C2 - 39529490

AN - SCOPUS:85208798750

SN - 2040-1116

VL - 16

SP - 163

EP - 168

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

IS - 1

ER -

Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this